Bruker Stock Today
BRKR Stock | USD 45.97 1.00 2.22% |
PerformanceVery Weak
| Odds Of DistressVery Low
|
Bruker is selling at 45.97 as of the 15th of March 2025; that is 2.22% increase since the beginning of the trading day. The stock's lowest day price was 44.88. Bruker has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on December 24, 2020, Representative Bob Gibbs of US Congress acquired under $15k worth of Bruker's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of August 2000 | Category Healthcare | Classification Health Care |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. The company has 151.7 M outstanding shares of which 4.61 M shares are currently shorted by private and institutional investors with about 3.27 trading days to cover. More on Bruker
Moving together with Bruker Stock
Moving against Bruker Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bruker Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
President and CEO, BEST | Burkhard Prause | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Midcap 400, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Life Sciences Tools & Services, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBruker can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bruker's financial leverage. It provides some insight into what part of Bruker's total assets is financed by creditors.
|
Bruker (BRKR) is traded on NASDAQ Exchange in USA. It is located in 40 Manning Road, Billerica, MA, United States, 01821 and employs 11,396 people. Bruker is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.97 B. Bruker conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 151.7 M outstanding shares of which 4.61 M shares are currently shorted by private and institutional investors with about 3.27 trading days to cover.
Bruker currently holds about 733.6 M in cash with 251.3 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Check Bruker Probability Of Bankruptcy
Ownership AllocationBruker holds a total of 151.7 Million outstanding shares. The majority of Bruker outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bruker to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bruker. Please pay attention to any change in the institutional holdings of Bruker as this could imply that something significant has changed or is about to change at the company. Also note that nearly twenty-two million three hundred thousand six hundred thirty-four invesors are currently shorting Bruker expressing very little confidence in its future performance.
Check Bruker Ownership Details
Bruker Stock Institutional Holders
Instituion | Recorded On | Shares | |
Geode Capital Management, Llc | 2024-12-31 | 2 M | |
Fidelity International Ltd | 2024-12-31 | 2 M | |
Oz Management Llc | 2024-12-31 | 1.7 M | |
Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.7 M | |
Ameriprise Financial Inc | 2024-12-31 | 1.6 M | |
Alyeska Investment Group, L.p. | 2024-12-31 | 1.5 M | |
Sg Capital Management, Llc | 2024-12-31 | 1.4 M | |
Td Asset Management Inc | 2024-12-31 | 1.4 M | |
Bank Of America Corp | 2024-12-31 | 1.4 M | |
Fmr Inc | 2024-12-31 | 13.8 M | |
T. Rowe Price Investment Management,inc. | 2024-12-31 | 12.4 M |
Bruker Historical Income Statement
Bruker Stock Against Markets
Bruker Corporate Management
Collin DSilva | Pres Division | Profile | |
Urban Faeh | Pres GmbH | Profile | |
Justin Ward | Senior Development | Profile | |
Stacey Desrochers | Treasurer Relations | Profile |
Additional Tools for Bruker Stock Analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.